$49 per month*
Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
The statistics highlights AstraZeneca’s Revenue by Segment, split between Covid- 19, new CVRM, oncology, rare diseases, respiratory, vaccines and immune, and other segments, reported quarterly from 2016 Q1 onwards.
|Covid 19 (deprecated)||–||–|
|Vaccines and immune||–||–|
The New CRVM segment has been a major source of revenue growth for the organization, showing consistent progress since 2016 Q1 and reaching its highest point of 2,557,000,000 GBP in 2023 Q1. This success can be attributed to factors like introducing new products, employing innovative market strategies, and effectively targeting customers.
Oncology is another significant segment that demonstrated substantial revenue growth throughout the analyzed period. Starting at 738,000,000 GBP in 2016 Q1, it steadily increased and reached 4,148,000,000 GBP in 2023 Q1. The growth in this area is attributed to the rising prevalence of oncological conditions, advancements in treatment options, and the organization’s strong presence in the oncology sector.
Respiratory also showed resilience in revenue generation, maintaining a steady revenue stream despite minor fluctuations, indicating a consistent market demand for respiratory-related products and effective response from the organization.
Vaccines & Immune Segment
The Vaccines & Immune segment displayed an interesting trend, reaching a significant peak of 1,814,000,000 GBP in 2021 Q1 but experiencing a decline in subsequent quarters, likely due to the completion of specific vaccine projects or changes in the market dynamics.
In addition to these segments, the revenue from COVID-19 drugs played a vital role in the organization’s financial performance. During the pandemic, the demand for COVID-19 therapeutics was high, and the organization capitalized on this opportunity. The revenue from COVID-19 drugs saw remarkable growth, peaking at 3,921,000,000 GBP in 2021 Q3, owing to the urgent global need for effective treatments.
Although the revenue from COVID-19 drugs may have fluctuated over time due to vaccination programs and improving global conditions, its significant contribution during the peak period highlights the organization’s role in the global pandemic response.
The Others segments, though experiencing some fluctuations, maintained a considerable share of the revenue stream. The Rare Disease segment, for example, demonstrated revenue growth, peaking at 1,866,000,000 GBP in 2022 Q3, reflecting the organization’s commitment to addressing unmet medical needs for rare disease patients.
About AstraZeneca PLC
AstraZeneca is a global biopharmaceutical company established in 1999 with a strong commitment to enhancing global health and well-being. Their primary focus is on research, development, and marketing of cutting-edge medications in various therapeutic fields like oncology, cardiovascular, respiratory, and immunology. Their mission revolves around advancing scientific frontiers and bringing transformative treatments to patients. AstraZeneca caters to a wide range of stakeholders, including patients, medical professionals, governments, and healthcare organizations, aiming to offer efficient and easily accessible healthcare solutions to meet unmet medical requirements on a global scale. It has been involved in developing the Oxford – AstraZeneca Covid 19 vaccine. It focuses on transforming the lives of people affected by rare diseases through the development of innovative medicines and supportive technologies and healthcare services.
Did you like AstraZeneca’s Revenue by Segment statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.